nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP3A4—bone cancer	0.559	1	CbGaD
Citalopram—CYP2B6—Cisplatin—bone cancer	0.0296	0.295	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—bone cancer	0.0199	0.198	CbGbCtD
Citalopram—ABCB1—Cisplatin—bone cancer	0.0152	0.151	CbGbCtD
Citalopram—ABCB1—Doxorubicin—bone cancer	0.0102	0.101	CbGbCtD
Citalopram—ABCB1—Methotrexate—bone cancer	0.00986	0.0982	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—bone cancer	0.00959	0.0955	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—bone cancer	0.0061	0.0608	CbGbCtD
Citalopram—Escitalopram—CYP3A4—bone cancer	0.00487	1	CrCbGaD
Citalopram—Urinary tract infection—Doxorubicin—bone cancer	0.00016	0.000576	CcSEcCtD
Citalopram—Haemorrhage—Epirubicin—bone cancer	0.00016	0.000575	CcSEcCtD
Citalopram—Hepatitis—Epirubicin—bone cancer	0.00016	0.000575	CcSEcCtD
Citalopram—Eye disorder—Methotrexate—bone cancer	0.000159	0.000574	CcSEcCtD
Citalopram—Tinnitus—Methotrexate—bone cancer	0.000159	0.000573	CcSEcCtD
Citalopram—Hypoaesthesia—Epirubicin—bone cancer	0.000159	0.000572	CcSEcCtD
Citalopram—Asthenia—Cisplatin—bone cancer	0.000158	0.00057	CcSEcCtD
Citalopram—Pharyngitis—Epirubicin—bone cancer	0.000158	0.00057	CcSEcCtD
Citalopram—Cardiac disorder—Methotrexate—bone cancer	0.000158	0.00057	CcSEcCtD
Citalopram—Sweating—Doxorubicin—bone cancer	0.000158	0.000568	CcSEcCtD
Citalopram—Urinary tract disorder—Epirubicin—bone cancer	0.000158	0.000568	CcSEcCtD
Citalopram—Oedema peripheral—Epirubicin—bone cancer	0.000157	0.000566	CcSEcCtD
Citalopram—Haematuria—Doxorubicin—bone cancer	0.000157	0.000565	CcSEcCtD
Citalopram—Connective tissue disorder—Epirubicin—bone cancer	0.000157	0.000565	CcSEcCtD
Citalopram—Urethral disorder—Epirubicin—bone cancer	0.000156	0.000563	CcSEcCtD
Citalopram—Hepatobiliary disease—Doxorubicin—bone cancer	0.000156	0.00056	CcSEcCtD
Citalopram—Epistaxis—Doxorubicin—bone cancer	0.000155	0.000559	CcSEcCtD
Citalopram—Angiopathy—Methotrexate—bone cancer	0.000155	0.000557	CcSEcCtD
Citalopram—Sinusitis—Doxorubicin—bone cancer	0.000154	0.000556	CcSEcCtD
Citalopram—Immune system disorder—Methotrexate—bone cancer	0.000154	0.000555	CcSEcCtD
Citalopram—Visual impairment—Epirubicin—bone cancer	0.000154	0.000554	CcSEcCtD
Citalopram—Mediastinal disorder—Methotrexate—bone cancer	0.000154	0.000553	CcSEcCtD
Citalopram—Agranulocytosis—Doxorubicin—bone cancer	0.000153	0.000553	CcSEcCtD
Citalopram—Chills—Methotrexate—bone cancer	0.000153	0.000551	CcSEcCtD
Citalopram—Diarrhoea—Cisplatin—bone cancer	0.000151	0.000544	CcSEcCtD
Citalopram—Erythema multiforme—Epirubicin—bone cancer	0.000151	0.000543	CcSEcCtD
Citalopram—Alopecia—Methotrexate—bone cancer	0.000151	0.000543	CcSEcCtD
Citalopram—Bradycardia—Doxorubicin—bone cancer	0.00015	0.000541	CcSEcCtD
Citalopram—Mental disorder—Methotrexate—bone cancer	0.000149	0.000538	CcSEcCtD
Citalopram—Eye disorder—Epirubicin—bone cancer	0.000149	0.000537	CcSEcCtD
Citalopram—Tinnitus—Epirubicin—bone cancer	0.000149	0.000536	CcSEcCtD
Citalopram—Erythema—Methotrexate—bone cancer	0.000148	0.000535	CcSEcCtD
Citalopram—Malnutrition—Methotrexate—bone cancer	0.000148	0.000535	CcSEcCtD
Citalopram—Haemoglobin—Doxorubicin—bone cancer	0.000148	0.000534	CcSEcCtD
Citalopram—Cardiac disorder—Epirubicin—bone cancer	0.000148	0.000533	CcSEcCtD
Citalopram—Flushing—Epirubicin—bone cancer	0.000148	0.000533	CcSEcCtD
Citalopram—Rhinitis—Doxorubicin—bone cancer	0.000148	0.000533	CcSEcCtD
Citalopram—Hepatitis—Doxorubicin—bone cancer	0.000148	0.000532	CcSEcCtD
Citalopram—Haemorrhage—Doxorubicin—bone cancer	0.000148	0.000532	CcSEcCtD
Citalopram—Hypoaesthesia—Doxorubicin—bone cancer	0.000147	0.000529	CcSEcCtD
Citalopram—Pharyngitis—Doxorubicin—bone cancer	0.000147	0.000528	CcSEcCtD
Citalopram—Urinary tract disorder—Doxorubicin—bone cancer	0.000146	0.000525	CcSEcCtD
Citalopram—Oedema peripheral—Doxorubicin—bone cancer	0.000145	0.000524	CcSEcCtD
Citalopram—Dysgeusia—Methotrexate—bone cancer	0.000145	0.000524	CcSEcCtD
Citalopram—Connective tissue disorder—Doxorubicin—bone cancer	0.000145	0.000523	CcSEcCtD
Citalopram—Angiopathy—Epirubicin—bone cancer	0.000145	0.000521	CcSEcCtD
Citalopram—Urethral disorder—Doxorubicin—bone cancer	0.000145	0.000521	CcSEcCtD
Citalopram—Immune system disorder—Epirubicin—bone cancer	0.000144	0.000519	CcSEcCtD
Citalopram—Mediastinal disorder—Epirubicin—bone cancer	0.000144	0.000518	CcSEcCtD
Citalopram—Back pain—Methotrexate—bone cancer	0.000144	0.000517	CcSEcCtD
Citalopram—Chills—Epirubicin—bone cancer	0.000143	0.000516	CcSEcCtD
Citalopram—Arrhythmia—Epirubicin—bone cancer	0.000143	0.000513	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—bone cancer	0.000142	0.000512	CcSEcCtD
Citalopram—Alopecia—Epirubicin—bone cancer	0.000141	0.000508	CcSEcCtD
Citalopram—Vomiting—Cisplatin—bone cancer	0.00014	0.000506	CcSEcCtD
Citalopram—Vision blurred—Methotrexate—bone cancer	0.00014	0.000504	CcSEcCtD
Citalopram—Mental disorder—Epirubicin—bone cancer	0.00014	0.000504	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—bone cancer	0.00014	0.000503	CcSEcCtD
Citalopram—Rash—Cisplatin—bone cancer	0.000139	0.000501	CcSEcCtD
Citalopram—Dermatitis—Cisplatin—bone cancer	0.000139	0.000501	CcSEcCtD
Citalopram—Malnutrition—Epirubicin—bone cancer	0.000139	0.0005	CcSEcCtD
Citalopram—Erythema—Epirubicin—bone cancer	0.000139	0.0005	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—bone cancer	0.000138	0.000497	CcSEcCtD
Citalopram—Ill-defined disorder—Methotrexate—bone cancer	0.000138	0.000496	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—bone cancer	0.000138	0.000496	CcSEcCtD
Citalopram—Anaemia—Methotrexate—bone cancer	0.000137	0.000494	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—bone cancer	0.000137	0.000494	CcSEcCtD
Citalopram—Flushing—Doxorubicin—bone cancer	0.000137	0.000494	CcSEcCtD
Citalopram—Flatulence—Epirubicin—bone cancer	0.000137	0.000493	CcSEcCtD
Citalopram—Tension—Epirubicin—bone cancer	0.000136	0.000491	CcSEcCtD
Citalopram—Dysgeusia—Epirubicin—bone cancer	0.000136	0.00049	CcSEcCtD
Citalopram—Nervousness—Epirubicin—bone cancer	0.000135	0.000486	CcSEcCtD
Citalopram—Back pain—Epirubicin—bone cancer	0.000134	0.000484	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—bone cancer	0.000134	0.000482	CcSEcCtD
Citalopram—Malaise—Methotrexate—bone cancer	0.000134	0.000482	CcSEcCtD
Citalopram—Muscle spasms—Epirubicin—bone cancer	0.000134	0.000481	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—bone cancer	0.000133	0.00048	CcSEcCtD
Citalopram—Vertigo—Methotrexate—bone cancer	0.000133	0.00048	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—bone cancer	0.000133	0.000479	CcSEcCtD
Citalopram—Leukopenia—Methotrexate—bone cancer	0.000133	0.000479	CcSEcCtD
Citalopram—Chills—Doxorubicin—bone cancer	0.000132	0.000477	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—bone cancer	0.000132	0.000475	CcSEcCtD
Citalopram—Nausea—Cisplatin—bone cancer	0.000131	0.000472	CcSEcCtD
Citalopram—Vision blurred—Epirubicin—bone cancer	0.000131	0.000472	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—bone cancer	0.00013	0.00047	CcSEcCtD
Citalopram—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00013	0.00223	CbGpPWpGaD
Citalopram—Cough—Methotrexate—bone cancer	0.00013	0.000467	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—bone cancer	0.000129	0.000466	CcSEcCtD
Citalopram—Ill-defined disorder—Epirubicin—bone cancer	0.000129	0.000464	CcSEcCtD
Citalopram—Convulsion—Methotrexate—bone cancer	0.000129	0.000463	CcSEcCtD
Citalopram—Erythema—Doxorubicin—bone cancer	0.000129	0.000463	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—bone cancer	0.000129	0.000463	CcSEcCtD
Citalopram—Anaemia—Epirubicin—bone cancer	0.000128	0.000462	CcSEcCtD
Citalopram—HTR2C—GPCR ligand binding—GRM1—bone cancer	0.000128	0.0022	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—GRM4—bone cancer	0.000128	0.0022	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—GRM4—bone cancer	0.000128	0.00219	CbGpPWpGaD
Citalopram—Agitation—Epirubicin—bone cancer	0.000128	0.00046	CcSEcCtD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000127	0.00218	CbGpPWpGaD
Citalopram—Flatulence—Doxorubicin—bone cancer	0.000127	0.000456	CcSEcCtD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000127	0.00217	CbGpPWpGaD
Citalopram—Myalgia—Methotrexate—bone cancer	0.000126	0.000455	CcSEcCtD
Citalopram—Arthralgia—Methotrexate—bone cancer	0.000126	0.000455	CcSEcCtD
Citalopram—Chest pain—Methotrexate—bone cancer	0.000126	0.000455	CcSEcCtD
Citalopram—Tension—Doxorubicin—bone cancer	0.000126	0.000454	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—bone cancer	0.000126	0.000453	CcSEcCtD
Citalopram—ADRA1A—GPCR ligand binding—GRM4—bone cancer	0.000126	0.00215	CbGpPWpGaD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000125	0.000452	CcSEcCtD
Citalopram—SLC6A4—Circadian rythm related genes—CDK4—bone cancer	0.000125	0.00215	CbGpPWpGaD
Citalopram—Malaise—Epirubicin—bone cancer	0.000125	0.000451	CcSEcCtD
Citalopram—Discomfort—Methotrexate—bone cancer	0.000125	0.00045	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—bone cancer	0.000125	0.00045	CcSEcCtD
Citalopram—Vertigo—Epirubicin—bone cancer	0.000125	0.000449	CcSEcCtD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000125	0.00214	CbGpPWpGaD
Citalopram—Syncope—Epirubicin—bone cancer	0.000125	0.000449	CcSEcCtD
Citalopram—Leukopenia—Epirubicin—bone cancer	0.000124	0.000448	CcSEcCtD
Citalopram—Back pain—Doxorubicin—bone cancer	0.000124	0.000448	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—bone cancer	0.000124	0.000445	CcSEcCtD
Citalopram—Palpitations—Epirubicin—bone cancer	0.000123	0.000442	CcSEcCtD
Citalopram—Confusional state—Methotrexate—bone cancer	0.000122	0.00044	CcSEcCtD
Citalopram—Loss of consciousness—Epirubicin—bone cancer	0.000122	0.00044	CcSEcCtD
Citalopram—Cough—Epirubicin—bone cancer	0.000121	0.000437	CcSEcCtD
Citalopram—Anaphylactic shock—Methotrexate—bone cancer	0.000121	0.000436	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—bone cancer	0.000121	0.000436	CcSEcCtD
Citalopram—Convulsion—Epirubicin—bone cancer	0.00012	0.000433	CcSEcCtD
Citalopram—Infection—Methotrexate—bone cancer	0.00012	0.000433	CcSEcCtD
Citalopram—Hypertension—Epirubicin—bone cancer	0.00012	0.000432	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—bone cancer	0.000119	0.00043	CcSEcCtD
Citalopram—Nervous system disorder—Methotrexate—bone cancer	0.000119	0.000428	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—bone cancer	0.000119	0.000428	CcSEcCtD
Citalopram—Thrombocytopenia—Methotrexate—bone cancer	0.000119	0.000427	CcSEcCtD
Citalopram—Chest pain—Epirubicin—bone cancer	0.000118	0.000426	CcSEcCtD
Citalopram—Myalgia—Epirubicin—bone cancer	0.000118	0.000426	CcSEcCtD
Citalopram—Arthralgia—Epirubicin—bone cancer	0.000118	0.000426	CcSEcCtD
Citalopram—Agitation—Doxorubicin—bone cancer	0.000118	0.000425	CcSEcCtD
Citalopram—Anxiety—Epirubicin—bone cancer	0.000118	0.000424	CcSEcCtD
Citalopram—Skin disorder—Methotrexate—bone cancer	0.000118	0.000424	CcSEcCtD
Citalopram—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000118	0.00202	CbGpPWpGaD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000117	0.000423	CcSEcCtD
Citalopram—Hyperhidrosis—Methotrexate—bone cancer	0.000117	0.000422	CcSEcCtD
Citalopram—Discomfort—Epirubicin—bone cancer	0.000117	0.000421	CcSEcCtD
Citalopram—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000116	0.00199	CbGpPWpGaD
Citalopram—Malaise—Doxorubicin—bone cancer	0.000116	0.000417	CcSEcCtD
Citalopram—Dry mouth—Epirubicin—bone cancer	0.000116	0.000417	CcSEcCtD
Citalopram—SLC6A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000116	0.00198	CbGpPWpGaD
Citalopram—Vertigo—Doxorubicin—bone cancer	0.000115	0.000416	CcSEcCtD
Citalopram—Anorexia—Methotrexate—bone cancer	0.000115	0.000416	CcSEcCtD
Citalopram—Syncope—Doxorubicin—bone cancer	0.000115	0.000415	CcSEcCtD
Citalopram—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000115	0.00197	CbGpPWpGaD
Citalopram—Leukopenia—Doxorubicin—bone cancer	0.000115	0.000414	CcSEcCtD
Citalopram—Confusional state—Epirubicin—bone cancer	0.000114	0.000412	CcSEcCtD
Citalopram—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000114	0.00195	CbGpPWpGaD
Citalopram—Palpitations—Doxorubicin—bone cancer	0.000114	0.000409	CcSEcCtD
Citalopram—Anaphylactic shock—Epirubicin—bone cancer	0.000113	0.000408	CcSEcCtD
Citalopram—Oedema—Epirubicin—bone cancer	0.000113	0.000408	CcSEcCtD
Citalopram—Hypotension—Methotrexate—bone cancer	0.000113	0.000408	CcSEcCtD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000113	0.00194	CbGpPWpGaD
Citalopram—Loss of consciousness—Doxorubicin—bone cancer	0.000113	0.000407	CcSEcCtD
Citalopram—Infection—Epirubicin—bone cancer	0.000113	0.000406	CcSEcCtD
Citalopram—Cough—Doxorubicin—bone cancer	0.000112	0.000404	CcSEcCtD
Citalopram—Shock—Epirubicin—bone cancer	0.000112	0.000402	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—bone cancer	0.000111	0.000401	CcSEcCtD
Citalopram—Nervous system disorder—Epirubicin—bone cancer	0.000111	0.0004	CcSEcCtD
Citalopram—HRH1—GPCR ligand binding—GRM1—bone cancer	0.000111	0.0019	CbGpPWpGaD
Citalopram—Thrombocytopenia—Epirubicin—bone cancer	0.000111	0.0004	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—bone cancer	0.000111	0.0004	CcSEcCtD
Citalopram—CHRM1—GPCR ligand binding—GRM1—bone cancer	0.000111	0.0019	CbGpPWpGaD
Citalopram—Tachycardia—Epirubicin—bone cancer	0.000111	0.000399	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00011	0.000398	CcSEcCtD
Citalopram—Skin disorder—Epirubicin—bone cancer	0.00011	0.000397	CcSEcCtD
Citalopram—Hyperhidrosis—Epirubicin—bone cancer	0.00011	0.000395	CcSEcCtD
Citalopram—Insomnia—Methotrexate—bone cancer	0.00011	0.000395	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—bone cancer	0.000109	0.000394	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—bone cancer	0.000109	0.000394	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—bone cancer	0.000109	0.000394	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—bone cancer	0.000109	0.000393	CcSEcCtD
Citalopram—ADRA1A—GPCR ligand binding—GRM1—bone cancer	0.000109	0.00187	CbGpPWpGaD
Citalopram—Paraesthesia—Methotrexate—bone cancer	0.000109	0.000392	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000109	0.000391	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—bone cancer	0.000108	0.000389	CcSEcCtD
Citalopram—Anorexia—Epirubicin—bone cancer	0.000108	0.000389	CcSEcCtD
Citalopram—Dyspnoea—Methotrexate—bone cancer	0.000108	0.000389	CcSEcCtD
Citalopram—Somnolence—Methotrexate—bone cancer	0.000108	0.000388	CcSEcCtD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000107	0.00184	CbGpPWpGaD
Citalopram—Dry mouth—Doxorubicin—bone cancer	0.000107	0.000385	CcSEcCtD
Citalopram—Dyspepsia—Methotrexate—bone cancer	0.000107	0.000384	CcSEcCtD
Citalopram—Hypotension—Epirubicin—bone cancer	0.000106	0.000382	CcSEcCtD
Citalopram—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000106	0.00181	CbGpPWpGaD
Citalopram—Confusional state—Doxorubicin—bone cancer	0.000106	0.000381	CcSEcCtD
Citalopram—Decreased appetite—Methotrexate—bone cancer	0.000105	0.000379	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—bone cancer	0.000105	0.000378	CcSEcCtD
Citalopram—Oedema—Doxorubicin—bone cancer	0.000105	0.000378	CcSEcCtD
Citalopram—Gastrointestinal disorder—Methotrexate—bone cancer	0.000105	0.000377	CcSEcCtD
Citalopram—Fatigue—Methotrexate—bone cancer	0.000104	0.000376	CcSEcCtD
Citalopram—Infection—Doxorubicin—bone cancer	0.000104	0.000375	CcSEcCtD
Citalopram—Pain—Methotrexate—bone cancer	0.000104	0.000373	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000103	0.000372	CcSEcCtD
Citalopram—Shock—Doxorubicin—bone cancer	0.000103	0.000372	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—bone cancer	0.000103	0.000371	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—bone cancer	0.000103	0.00037	CcSEcCtD
Citalopram—Insomnia—Epirubicin—bone cancer	0.000103	0.000369	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—bone cancer	0.000102	0.000369	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—bone cancer	0.000102	0.000367	CcSEcCtD
Citalopram—Paraesthesia—Epirubicin—bone cancer	0.000102	0.000367	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—bone cancer	0.000101	0.000365	CcSEcCtD
Citalopram—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000101	0.00174	CbGpPWpGaD
Citalopram—Dyspnoea—Epirubicin—bone cancer	0.000101	0.000364	CcSEcCtD
Citalopram—Somnolence—Epirubicin—bone cancer	0.000101	0.000363	CcSEcCtD
Citalopram—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000101	0.00172	CbGpPWpGaD
Citalopram—Anorexia—Doxorubicin—bone cancer	0.0001	0.00036	CcSEcCtD
Citalopram—Feeling abnormal—Methotrexate—bone cancer	9.98e-05	0.00036	CcSEcCtD
Citalopram—Dyspepsia—Epirubicin—bone cancer	9.98e-05	0.000359	CcSEcCtD
Citalopram—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	9.92e-05	0.0017	CbGpPWpGaD
Citalopram—Gastrointestinal pain—Methotrexate—bone cancer	9.9e-05	0.000357	CcSEcCtD
Citalopram—SLC6A4—SIDS Susceptibility Pathways—JUN—bone cancer	9.9e-05	0.0017	CbGpPWpGaD
Citalopram—Decreased appetite—Epirubicin—bone cancer	9.85e-05	0.000355	CcSEcCtD
Citalopram—CYP2E1—Biological oxidations—GSTP1—bone cancer	9.85e-05	0.00169	CbGpPWpGaD
Citalopram—Hypotension—Doxorubicin—bone cancer	9.8e-05	0.000353	CcSEcCtD
Citalopram—Gastrointestinal disorder—Epirubicin—bone cancer	9.79e-05	0.000353	CcSEcCtD
Citalopram—Fatigue—Epirubicin—bone cancer	9.77e-05	0.000352	CcSEcCtD
Citalopram—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	9.72e-05	0.00167	CbGpPWpGaD
Citalopram—Constipation—Epirubicin—bone cancer	9.69e-05	0.000349	CcSEcCtD
Citalopram—Pain—Epirubicin—bone cancer	9.69e-05	0.000349	CcSEcCtD
Citalopram—Urticaria—Methotrexate—bone cancer	9.62e-05	0.000347	CcSEcCtD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	9.62e-05	0.00165	CbGpPWpGaD
Citalopram—Abdominal pain—Methotrexate—bone cancer	9.57e-05	0.000345	CcSEcCtD
Citalopram—Body temperature increased—Methotrexate—bone cancer	9.57e-05	0.000345	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—bone cancer	9.56e-05	0.000344	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—bone cancer	9.49e-05	0.000342	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—bone cancer	9.42e-05	0.000339	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—bone cancer	9.35e-05	0.000337	CcSEcCtD
Citalopram—Feeling abnormal—Epirubicin—bone cancer	9.34e-05	0.000336	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—bone cancer	9.32e-05	0.000336	CcSEcCtD
Citalopram—Gastrointestinal pain—Epirubicin—bone cancer	9.27e-05	0.000334	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—bone cancer	9.23e-05	0.000333	CcSEcCtD
Citalopram—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	9.14e-05	0.00157	CbGpPWpGaD
Citalopram—Decreased appetite—Doxorubicin—bone cancer	9.12e-05	0.000328	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—bone cancer	9.05e-05	0.000326	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—bone cancer	9.04e-05	0.000326	CcSEcCtD
Citalopram—HTR2C—GPCR ligand binding—SMO—bone cancer	9.03e-05	0.00155	CbGpPWpGaD
Citalopram—Urticaria—Epirubicin—bone cancer	9e-05	0.000324	CcSEcCtD
Citalopram—Pain—Doxorubicin—bone cancer	8.97e-05	0.000323	CcSEcCtD
Citalopram—Constipation—Doxorubicin—bone cancer	8.97e-05	0.000323	CcSEcCtD
Citalopram—Abdominal pain—Epirubicin—bone cancer	8.96e-05	0.000323	CcSEcCtD
Citalopram—Body temperature increased—Epirubicin—bone cancer	8.96e-05	0.000323	CcSEcCtD
Citalopram—Hypersensitivity—Methotrexate—bone cancer	8.92e-05	0.000321	CcSEcCtD
Citalopram—CYP2C19—Biological oxidations—CYP3A4—bone cancer	8.89e-05	0.00152	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	8.81e-05	0.00151	CbGpPWpGaD
Citalopram—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	8.77e-05	0.0015	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	8.76e-05	0.0015	CbGpPWpGaD
Citalopram—Asthenia—Methotrexate—bone cancer	8.69e-05	0.000313	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—bone cancer	8.64e-05	0.000311	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—bone cancer	8.58e-05	0.000309	CcSEcCtD
Citalopram—Pruritus—Methotrexate—bone cancer	8.57e-05	0.000309	CcSEcCtD
Citalopram—SLC6A3—Transmission across Chemical Synapses—BRAF—bone cancer	8.49e-05	0.00145	CbGpPWpGaD
Citalopram—CHRM1—Regulation of Actin Cytoskeleton—BRAF—bone cancer	8.44e-05	0.00145	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—GRM4—bone cancer	8.36e-05	0.00143	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—RGS1—bone cancer	8.36e-05	0.00143	CbGpPWpGaD
Citalopram—Hypersensitivity—Epirubicin—bone cancer	8.35e-05	0.000301	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—bone cancer	8.33e-05	0.0003	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—bone cancer	8.29e-05	0.000299	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—bone cancer	8.29e-05	0.000299	CcSEcCtD
Citalopram—Diarrhoea—Methotrexate—bone cancer	8.29e-05	0.000299	CcSEcCtD
Citalopram—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	8.24e-05	0.00141	CbGpPWpGaD
Citalopram—CYP2D6—Biological oxidations—CYP3A4—bone cancer	8.18e-05	0.0014	CbGpPWpGaD
Citalopram—Asthenia—Epirubicin—bone cancer	8.13e-05	0.000293	CcSEcCtD
Citalopram—SLC6A4—Circadian rythm related genes—JUN—bone cancer	8.08e-05	0.00138	CbGpPWpGaD
Citalopram—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	8.06e-05	0.00138	CbGpPWpGaD
Citalopram—Pruritus—Epirubicin—bone cancer	8.02e-05	0.000289	CcSEcCtD
Citalopram—Dizziness—Methotrexate—bone cancer	8.01e-05	0.000289	CcSEcCtD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	7.98e-05	0.00137	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	7.95e-05	0.00136	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.87e-05	0.00135	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—SMO—bone cancer	7.83e-05	0.00134	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—SMO—bone cancer	7.8e-05	0.00134	CbGpPWpGaD
Citalopram—Diarrhoea—Epirubicin—bone cancer	7.76e-05	0.000279	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—bone cancer	7.73e-05	0.000278	CcSEcCtD
Citalopram—Vomiting—Methotrexate—bone cancer	7.7e-05	0.000277	CcSEcCtD
Citalopram—ADRA1A—GPCR ligand binding—SMO—bone cancer	7.68e-05	0.00132	CbGpPWpGaD
Citalopram—Rash—Methotrexate—bone cancer	7.64e-05	0.000275	CcSEcCtD
Citalopram—Dermatitis—Methotrexate—bone cancer	7.63e-05	0.000275	CcSEcCtD
Citalopram—CYP2C19—Biological oxidations—GSTP1—bone cancer	7.6e-05	0.0013	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—GRM4—bone cancer	7.59e-05	0.0013	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—RGS1—bone cancer	7.59e-05	0.0013	CbGpPWpGaD
Citalopram—Headache—Methotrexate—bone cancer	7.59e-05	0.000273	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—bone cancer	7.52e-05	0.000271	CcSEcCtD
Citalopram—CHRM1—Circadian rythm related genes—CDK4—bone cancer	7.51e-05	0.00129	CbGpPWpGaD
Citalopram—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	7.5e-05	0.00128	CbGpPWpGaD
Citalopram—Dizziness—Epirubicin—bone cancer	7.5e-05	0.00027	CcSEcCtD
Citalopram—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	7.46e-05	0.00128	CbGpPWpGaD
Citalopram—Pruritus—Doxorubicin—bone cancer	7.42e-05	0.000267	CcSEcCtD
Citalopram—ADRA1A—AMPK Signaling—TP53—bone cancer	7.39e-05	0.00127	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—GRM1—bone cancer	7.25e-05	0.00124	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—RGS1—bone cancer	7.24e-05	0.00124	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—GRM4—bone cancer	7.24e-05	0.00124	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—GRM4—bone cancer	7.22e-05	0.00124	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—RGS1—bone cancer	7.22e-05	0.00124	CbGpPWpGaD
Citalopram—Vomiting—Epirubicin—bone cancer	7.21e-05	0.00026	CcSEcCtD
Citalopram—Nausea—Methotrexate—bone cancer	7.19e-05	0.000259	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—bone cancer	7.18e-05	0.000258	CcSEcCtD
Citalopram—Rash—Epirubicin—bone cancer	7.15e-05	0.000257	CcSEcCtD
Citalopram—Dermatitis—Epirubicin—bone cancer	7.14e-05	0.000257	CcSEcCtD
Citalopram—SLC6A3—Transmission across Chemical Synapses—MDM2—bone cancer	7.11e-05	0.00122	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—RGS1—bone cancer	7.11e-05	0.00122	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—GRM4—bone cancer	7.11e-05	0.00122	CbGpPWpGaD
Citalopram—Headache—Epirubicin—bone cancer	7.1e-05	0.000256	CcSEcCtD
Citalopram—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.06e-05	0.00121	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NDUFA12—bone cancer	7.05e-05	0.00121	CbGpPWpGaD
Citalopram—CYP2D6—Biological oxidations—GSTP1—bone cancer	6.99e-05	0.0012	CbGpPWpGaD
Citalopram—Dizziness—Doxorubicin—bone cancer	6.94e-05	0.00025	CcSEcCtD
Citalopram—CYP1A2—Biological oxidations—CYP3A4—bone cancer	6.93e-05	0.00119	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—NDUFA12—bone cancer	6.91e-05	0.00118	CbGpPWpGaD
Citalopram—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	6.9e-05	0.00118	CbGpPWpGaD
Citalopram—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	6.83e-05	0.00117	CbGpPWpGaD
Citalopram—Nausea—Epirubicin—bone cancer	6.73e-05	0.000243	CcSEcCtD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6.67e-05	0.00114	CbGpPWpGaD
Citalopram—Vomiting—Doxorubicin—bone cancer	6.67e-05	0.00024	CcSEcCtD
Citalopram—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.65e-05	0.00114	CbGpPWpGaD
Citalopram—Rash—Doxorubicin—bone cancer	6.61e-05	0.000238	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—bone cancer	6.61e-05	0.000238	CcSEcCtD
Citalopram—HTR2C—Signaling by GPCR—GRM1—bone cancer	6.58e-05	0.00113	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—RGS1—bone cancer	6.58e-05	0.00113	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—GRM4—bone cancer	6.58e-05	0.00113	CbGpPWpGaD
Citalopram—Headache—Doxorubicin—bone cancer	6.57e-05	0.000237	CcSEcCtD
Citalopram—CHRM1—Signaling by GPCR—RGS1—bone cancer	6.55e-05	0.00112	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—GRM4—bone cancer	6.55e-05	0.00112	CbGpPWpGaD
Citalopram—SLC6A3—Neuronal System—BRAF—bone cancer	6.5e-05	0.00111	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—GRM4—bone cancer	6.45e-05	0.00111	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—RGS1—bone cancer	6.45e-05	0.00111	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—GRM1—bone cancer	6.28e-05	0.00108	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—GRM1—bone cancer	6.26e-05	0.00107	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	6.25e-05	0.00107	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	6.25e-05	0.00107	CbGpPWpGaD
Citalopram—Nausea—Doxorubicin—bone cancer	6.23e-05	0.000224	CcSEcCtD
Citalopram—ADRA1A—GPCR downstream signaling—GRM1—bone cancer	6.16e-05	0.00106	CbGpPWpGaD
Citalopram—CYP1A2—Biological oxidations—GSTP1—bone cancer	5.92e-05	0.00102	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NT5C3A—bone cancer	5.84e-05	0.001	CbGpPWpGaD
Citalopram—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	5.84e-05	0.001	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.74e-05	0.000984	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—NT5C3A—bone cancer	5.72e-05	0.000981	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—GRM1—bone cancer	5.7e-05	0.000977	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—GRM1—bone cancer	5.68e-05	0.000974	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—GRM1—bone cancer	5.59e-05	0.000959	CbGpPWpGaD
Citalopram—SLC6A3—Neuronal System—MDM2—bone cancer	5.45e-05	0.000934	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—TP53—bone cancer	5.33e-05	0.000914	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NDUFA12—bone cancer	5.33e-05	0.000913	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NDUFA12—bone cancer	5.2e-05	0.000891	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.95e-05	0.000848	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NDUFA12—bone cancer	4.9e-05	0.00084	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—JUN—bone cancer	4.84e-05	0.000829	CbGpPWpGaD
Citalopram—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	4.83e-05	0.000828	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—GNA11—bone cancer	4.67e-05	0.0008	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—SMO—bone cancer	4.64e-05	0.000795	CbGpPWpGaD
Citalopram—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.57e-05	0.000783	CbGpPWpGaD
Citalopram—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.51e-05	0.000773	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RGS1—bone cancer	4.48e-05	0.000768	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—GRM4—bone cancer	4.48e-05	0.000768	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NT5C3A—bone cancer	4.41e-05	0.000757	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NT5C3A—bone cancer	4.31e-05	0.000738	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—GNA11—bone cancer	4.24e-05	0.000727	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—IL3—bone cancer	4.23e-05	0.000725	CbGpPWpGaD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	4.17e-05	0.000715	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NDUFA12—bone cancer	4.15e-05	0.000711	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NT5C3A—bone cancer	4.06e-05	0.000696	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—GNA11—bone cancer	4.05e-05	0.000693	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—GNA11—bone cancer	4.03e-05	0.000691	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—SMO—bone cancer	4.02e-05	0.000688	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—SMO—bone cancer	4e-05	0.000686	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—GNA11—bone cancer	3.97e-05	0.00068	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—SMO—bone cancer	3.94e-05	0.000676	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—GRM1—bone cancer	3.89e-05	0.000666	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—GRM4—bone cancer	3.88e-05	0.000666	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RGS1—bone cancer	3.88e-05	0.000666	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—GRM4—bone cancer	3.87e-05	0.000664	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RGS1—bone cancer	3.87e-05	0.000664	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL3—bone cancer	3.84e-05	0.000659	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—GRM4—bone cancer	3.81e-05	0.000653	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RGS1—bone cancer	3.81e-05	0.000653	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—GNA11—bone cancer	3.67e-05	0.00063	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—IL3—bone cancer	3.67e-05	0.000629	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.67e-05	0.000628	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—GNA11—bone cancer	3.66e-05	0.000628	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—IL3—bone cancer	3.66e-05	0.000627	CbGpPWpGaD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.62e-05	0.00062	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—GNA11—bone cancer	3.61e-05	0.000618	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.6e-05	0.000618	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—IL3—bone cancer	3.6e-05	0.000617	CbGpPWpGaD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.55e-05	0.000608	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.53e-05	0.000606	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NT5C3A—bone cancer	3.44e-05	0.00059	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—GRM1—bone cancer	3.37e-05	0.000577	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—GRM1—bone cancer	3.36e-05	0.000575	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL3—bone cancer	3.33e-05	0.000571	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL3—bone cancer	3.32e-05	0.000569	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—GRM1—bone cancer	3.31e-05	0.000566	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL3—bone cancer	3.27e-05	0.00056	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NDUFA12—bone cancer	3.2e-05	0.000549	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—TP53—bone cancer	3.19e-05	0.000547	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.19e-05	0.000546	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SMO—bone cancer	2.74e-05	0.000469	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NT5C3A—bone cancer	2.65e-05	0.000455	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ENO2—bone cancer	2.56e-05	0.000439	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ENO2—bone cancer	2.51e-05	0.00043	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.51e-05	0.000429	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—GNA11—bone cancer	2.5e-05	0.000429	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—DHFR—bone cancer	2.37e-05	0.000407	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SMO—bone cancer	2.37e-05	0.000407	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SMO—bone cancer	2.37e-05	0.000405	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ATF1—bone cancer	2.33e-05	0.000399	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SMO—bone cancer	2.33e-05	0.000399	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—DHFR—bone cancer	2.33e-05	0.000398	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL3—bone cancer	2.27e-05	0.000389	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GNA11—bone cancer	2.22e-05	0.00038	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GNA11—bone cancer	2.17e-05	0.000372	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—GNA11—bone cancer	2.17e-05	0.000372	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—GNA11—bone cancer	2.16e-05	0.000371	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—GNA11—bone cancer	2.13e-05	0.000365	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.1e-05	0.000361	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ATF1—bone cancer	2.02e-05	0.000346	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CYP3A4—bone cancer	2.01e-05	0.000345	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ATF1—bone cancer	2.01e-05	0.000345	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ATF1—bone cancer	1.98e-05	0.000339	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CYP3A4—bone cancer	1.97e-05	0.000338	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL3—bone cancer	1.97e-05	0.000337	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL3—bone cancer	1.96e-05	0.000336	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TGFBR2—bone cancer	1.94e-05	0.000333	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ENO2—bone cancer	1.93e-05	0.000331	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL3—bone cancer	1.93e-05	0.000331	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ENO2—bone cancer	1.89e-05	0.000323	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IGF1R—bone cancer	1.83e-05	0.000313	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—DHFR—bone cancer	1.79e-05	0.000307	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ENO2—bone cancer	1.78e-05	0.000305	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—DHFR—bone cancer	1.75e-05	0.0003	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GSTP1—bone cancer	1.72e-05	0.000295	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GSTP1—bone cancer	1.69e-05	0.000289	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TGFBR2—bone cancer	1.68e-05	0.000288	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TGFBR2—bone cancer	1.68e-05	0.000287	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GNA11—bone cancer	1.68e-05	0.000287	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TGFBR2—bone cancer	1.65e-05	0.000283	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—DHFR—bone cancer	1.65e-05	0.000283	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GNA11—bone cancer	1.64e-05	0.00028	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IGF1R—bone cancer	1.58e-05	0.000271	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IGF1R—bone cancer	1.58e-05	0.00027	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IGF1R—bone cancer	1.55e-05	0.000266	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GNA11—bone cancer	1.54e-05	0.000264	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP3A4—bone cancer	1.52e-05	0.000261	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.51e-05	0.000259	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ENO2—bone cancer	1.51e-05	0.000258	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP3A4—bone cancer	1.48e-05	0.000254	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP3A4—bone cancer	1.4e-05	0.00024	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—DHFR—bone cancer	1.4e-05	0.00024	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KIT—bone cancer	1.33e-05	0.000227	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GNA11—bone cancer	1.31e-05	0.000224	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTP1—bone cancer	1.3e-05	0.000223	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTP1—bone cancer	1.27e-05	0.000217	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—BRAF—bone cancer	1.25e-05	0.000213	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—EGFR—bone cancer	1.21e-05	0.000207	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTP1—bone cancer	1.2e-05	0.000205	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP3A4—bone cancer	1.18e-05	0.000203	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.18e-05	0.000202	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ENO2—bone cancer	1.16e-05	0.000199	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KIT—bone cancer	1.15e-05	0.000197	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KIT—bone cancer	1.14e-05	0.000196	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KIT—bone cancer	1.13e-05	0.000193	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—BRAF—bone cancer	1.08e-05	0.000185	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—DHFR—bone cancer	1.08e-05	0.000185	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—BRAF—bone cancer	1.08e-05	0.000184	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—BRAF—bone cancer	1.06e-05	0.000182	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—EGFR—bone cancer	1.05e-05	0.000179	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MDM2—bone cancer	1.04e-05	0.000179	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—EGFR—bone cancer	1.04e-05	0.000179	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—bone cancer	1.03e-05	0.000176	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTP1—bone cancer	1.01e-05	0.000174	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GNA11—bone cancer	1.01e-05	0.000173	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—JUN—bone cancer	9.07e-06	0.000155	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MDM2—bone cancer	9.04e-06	0.000155	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MDM2—bone cancer	9.01e-06	0.000154	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—bone cancer	8.91e-06	0.000153	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MDM2—bone cancer	8.87e-06	0.000152	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—bone cancer	8.83e-06	0.000151	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—bone cancer	8.73e-06	0.00015	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—JUN—bone cancer	7.86e-06	0.000135	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—JUN—bone cancer	7.84e-06	0.000134	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—bone cancer	7.82e-06	0.000134	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—JUN—bone cancer	7.71e-06	0.000132	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—bone cancer	7.65e-06	0.000131	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—bone cancer	7.62e-06	0.000131	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—bone cancer	7.5e-06	0.000129	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—bone cancer	7.13e-06	0.000122	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—bone cancer	6.73e-06	0.000115	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—bone cancer	6.57e-06	0.000113	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—bone cancer	6.19e-06	0.000106	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—bone cancer	6.18e-06	0.000106	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—bone cancer	6.16e-06	0.000106	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—bone cancer	6.06e-06	0.000104	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—bone cancer	5.99e-06	0.000103	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—bone cancer	5.25e-06	8.99e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—bone cancer	5.19e-06	8.89e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—bone cancer	5.17e-06	8.86e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—bone cancer	5.09e-06	8.73e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—bone cancer	4.05e-06	6.94e-05	CbGpPWpGaD
